Alcami to Provide Manufacturing Services for Trevena’s Pain Management Injection

Article

Alcami will provide services for Trevena’s OLINVYK (oliceridine) injection, an opioid approved for the management of acute pain severe enough to require an intravenous opioid analgesic in adults.

Alcami, a US-based contract development and manufacturing organization, announced on Aug. 26, 2020 that it will provide commercial manufacturing services for Trevena’s OLINVYK (oliceridine) injection, an opioid approved for the management of acute pain severe enough to require an intravenous opioid analgesic in adults.

“For Alcami, this is another example of our ability to partner with customers to provide comprehensive support services from development through commercial approval," said Walt Kaczmarek, CEO of Alcami, in the press release. "We congratulate Trevena on their novel product offering and important advancement in pain therapy and are proud to offer our expertise and support.”

Source: Alcami

Recent Videos
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Behind the Headlines, episode 7
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Related Content